Manufacturing methods for new drugs could be made greener and more efficient with the help of marine microbes.
Manufacturing methods for new drugs could be made greener and more efficient with the help of marine microbes. The project, which is being conducted by researchers at Heriot-Watt University (Edinburgh) and Plymouth Marine Laboratory (Plymouth, UK) in collaboration with Ingenza Ltd (Midlothian, UK), will use biochemical techniques to identify potentially useful enzymes in marine microbes.
"We are looking to find naturally occurring microbes that already have a built-in capacity to do the chemical reactions we want to perform in industry," said Robert Speight, operations director at Ingenza, in a statement. "There is every possibility of developing more efficient and sustainable manufacturing solutions-for pharmaceuticals and agrochemicals in particular-as a result of this search."
The team will be specifically looking for enzymes that can convert compounds that would previously have been waste products in the manufacturing process into the desired product. After finding these enzymes, the researchers will attempt to produce them in higher yield by treating the microbes under specific conditions. "The enzymes then undergo systematic testing to evaluate their activity, which enables us to pinpoint candidates that exhibit the best performance," Mark Keane, director of postgraduate research in the School ofEngineering & Physical Sciences at Heriot-Watt University, said in the statement.
The work was funded by the UK's Biotechnology and Biological Sciences Research Council (BBSRC) and the Technology Strategy Board. In the statement, Doug Kell, chief executive professor of the BBSRC, said: "Green and White biotechnologies are going to be an increasingly important part of the manufacturing landscape. Looking to biological systems that have been finely tuned by evolution to solve problems, rather than starting from scratch every time, might seem an obvious thing to do. It does, however, require the bringing together of particular niche expertise."
Stephanie Sutton is an assistant editor with PharmTech Europe.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.